The Dominant-Negative TNF (DN-TNF) Platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF) without interfering with trans-membrane TNF or TNF receptors. Key development programs include INKmune (Phase 1 for high-risk myelodysplastic syndrome), INB03 (Phase II for breast cancer), and XPro1595 (for Alzheimer's disease and treatment resistant depression).
Cyborg Score Rationale
Losses increased to $42.08 million in 2024 (40.2% higher than 2023), and the experimental Alzheimer's drug (XPro) failed to meet primary endpoints in the Phase 2 MINDFuL trial, representing a significant setback. However, the company maintains multiple clinical programs and recent capital raises suggest operational continuity.
Top Insights
XPro failed primary cognitive endpoints in Phase 2 Alzheimer's trial, a critical clinical setback for the company's most advanced CNS program
INKmune platform primes NK cells to target minimal residual disease and is in trials for metastatic castration-resistant prostate cancer
2024 revenue collapsed 90.97% to $14,000 while losses expanded to $42.08 million
Analyst consensus is Hold with 12-month price target of $4.30 (230% upside from recent trading levels)
Named Competitors
CAR-T Cell Immunotherapy — Cell-based cancer immunotherapy
PD-1/PD-L1 Checkpoint Inhibitors — Checkpoint inhibitor cancer treatments
TNF Inhibitors — Anti-TNF therapies for inflammation
Recent Developments
(January 2026) CEO David Moss letter to investors
(December 2025) Published results on inflammation research
(November 2025) Presentations at Clinical Trials Summit on two programs
Open the full interactive INmune Bio Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.